Cargando…
Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
BACKGROUND: Thrombosis in COVID-19 worsens mortality. In our study, we sought to investigate how the dose and type of anticoagulation (AC) can influence patient outcomes. METHODS: This is a single-center retrospective analysis of critically ill intubated patients with COVID-19, comparing low-molecul...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212478/ https://www.ncbi.nlm.nih.gov/pubmed/35716998 http://dx.doi.org/10.1016/j.jvsv.2022.04.019 |
_version_ | 1784730603930779648 |
---|---|
author | Volteas, Panagiotis Drakos, Panagiotis Alkadaa, Leor N. Cleri, Nathaniel A. Asencio, Anthony A. Oganov, Anthony Giannopoulos, Stefanos Saadon, Jordan R. Mikell, Charles B. Rubano, Jerry A. Labropoulos, Nicos Tassiopoulos, Apostolos K. Mofakham, Sima Bannazadeh, Mohsen |
author_facet | Volteas, Panagiotis Drakos, Panagiotis Alkadaa, Leor N. Cleri, Nathaniel A. Asencio, Anthony A. Oganov, Anthony Giannopoulos, Stefanos Saadon, Jordan R. Mikell, Charles B. Rubano, Jerry A. Labropoulos, Nicos Tassiopoulos, Apostolos K. Mofakham, Sima Bannazadeh, Mohsen |
author_sort | Volteas, Panagiotis |
collection | PubMed |
description | BACKGROUND: Thrombosis in COVID-19 worsens mortality. In our study, we sought to investigate how the dose and type of anticoagulation (AC) can influence patient outcomes. METHODS: This is a single-center retrospective analysis of critically ill intubated patients with COVID-19, comparing low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) at therapeutic and prophylactic doses. Of 218 patients, 135 received LMWH (70 prophylactic, 65 therapeutic) and 83 UFH (11 prophylactic, 72 therapeutic). The primary outcome was mortality. Secondary outcomes were thromboembolic complications confirmed on imaging and major bleeding complications. Cox proportional-hazards regression models were used to determine whether the type and dose of AC were independent predictors of survival. We performed Kaplan-Meier survival analysis to compare the cumulative survivals. RESULTS: Overall, therapeutic AC, with either LMWH (65% vs 79%, P = .09) or UFH (32% vs 46%, P = .73), conveyed no survival benefit over prophylactic AC. UFH was associated with a higher mortality rate than LMWH (66% vs 28%, P = .001), which was also evident in the multivariable analysis (LMWH vs UFH mortality, hazard ratio: 0.47, P = .001) and in the Kaplan-Meier survival analysis. Thrombotic and bleeding complications did not depend on the AC type (prophylactic LMWH vs UFH: thrombosis P = .49, bleeding P = .075; therapeutic LMWH vs UFH: thrombosis P = .5, bleeding P = .17). When comparing prophylactic with therapeutic AC, the rate of both thrombotic and bleeding complications was higher with the use of LMWH compared with UFH. In addition, transfusion requirements were significantly higher with both therapeutic LMWH and UFH. CONCLUSIONS: Among intubated critically ill COVID-19 intensive care unit patients, therapeutic AC, with either LMWH or UFH, conveyed no survival benefit over prophylactic AC. AC with LMWH was associated with higher cumulative survival compared with AC with UFH. |
format | Online Article Text |
id | pubmed-9212478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-92124782022-06-22 Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients Volteas, Panagiotis Drakos, Panagiotis Alkadaa, Leor N. Cleri, Nathaniel A. Asencio, Anthony A. Oganov, Anthony Giannopoulos, Stefanos Saadon, Jordan R. Mikell, Charles B. Rubano, Jerry A. Labropoulos, Nicos Tassiopoulos, Apostolos K. Mofakham, Sima Bannazadeh, Mohsen J Vasc Surg Venous Lymphat Disord Clinical Research Study BACKGROUND: Thrombosis in COVID-19 worsens mortality. In our study, we sought to investigate how the dose and type of anticoagulation (AC) can influence patient outcomes. METHODS: This is a single-center retrospective analysis of critically ill intubated patients with COVID-19, comparing low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) at therapeutic and prophylactic doses. Of 218 patients, 135 received LMWH (70 prophylactic, 65 therapeutic) and 83 UFH (11 prophylactic, 72 therapeutic). The primary outcome was mortality. Secondary outcomes were thromboembolic complications confirmed on imaging and major bleeding complications. Cox proportional-hazards regression models were used to determine whether the type and dose of AC were independent predictors of survival. We performed Kaplan-Meier survival analysis to compare the cumulative survivals. RESULTS: Overall, therapeutic AC, with either LMWH (65% vs 79%, P = .09) or UFH (32% vs 46%, P = .73), conveyed no survival benefit over prophylactic AC. UFH was associated with a higher mortality rate than LMWH (66% vs 28%, P = .001), which was also evident in the multivariable analysis (LMWH vs UFH mortality, hazard ratio: 0.47, P = .001) and in the Kaplan-Meier survival analysis. Thrombotic and bleeding complications did not depend on the AC type (prophylactic LMWH vs UFH: thrombosis P = .49, bleeding P = .075; therapeutic LMWH vs UFH: thrombosis P = .5, bleeding P = .17). When comparing prophylactic with therapeutic AC, the rate of both thrombotic and bleeding complications was higher with the use of LMWH compared with UFH. In addition, transfusion requirements were significantly higher with both therapeutic LMWH and UFH. CONCLUSIONS: Among intubated critically ill COVID-19 intensive care unit patients, therapeutic AC, with either LMWH or UFH, conveyed no survival benefit over prophylactic AC. AC with LMWH was associated with higher cumulative survival compared with AC with UFH. Elsevier Inc 2022-09 2022-06-15 /pmc/articles/PMC9212478/ /pubmed/35716998 http://dx.doi.org/10.1016/j.jvsv.2022.04.019 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Clinical Research Study Volteas, Panagiotis Drakos, Panagiotis Alkadaa, Leor N. Cleri, Nathaniel A. Asencio, Anthony A. Oganov, Anthony Giannopoulos, Stefanos Saadon, Jordan R. Mikell, Charles B. Rubano, Jerry A. Labropoulos, Nicos Tassiopoulos, Apostolos K. Mofakham, Sima Bannazadeh, Mohsen Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients |
title | Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients |
title_full | Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients |
title_fullStr | Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients |
title_full_unstemmed | Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients |
title_short | Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients |
title_sort | low-molecular-weight heparin compared with unfractionated heparin in critically ill covid-19 patients |
topic | Clinical Research Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212478/ https://www.ncbi.nlm.nih.gov/pubmed/35716998 http://dx.doi.org/10.1016/j.jvsv.2022.04.019 |
work_keys_str_mv | AT volteaspanagiotis lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT drakospanagiotis lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT alkadaaleorn lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT clerinathaniela lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT asencioanthonya lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT oganovanthony lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT giannopoulosstefanos lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT saadonjordanr lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT mikellcharlesb lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT rubanojerrya lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT labropoulosnicos lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT tassiopoulosapostolosk lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT mofakhamsima lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients AT bannazadehmohsen lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients |